The increasing concern about antibiotic-resistance has led to the search for alternative antimicrobial agents. In this effort, different metal oxide nanomaterials are currently under investigation, in order to assess their effectiveness, safety and mode of action. This study focused on CuO nanoparticles (CuO NPs) and was aimed at evaluating how the properties and the antimicrobial activity of these nanomaterials may be affected by the interaction with ligands present in biological and environmental media. Ligands can attach to the surface of particles and/or contribute to their dissolution through ligand-assisted ion release and the formation of complexes with copper ions. Eight natural amino acids (L-Arg, L-Asp, L-Glu, L-Cys, L-Val, L-Leu, L-Phe, L-Tyr) were chosen as model molecules to investigate these interactions and the toxicity of the obtained materials against the Gram-positive bacterium Staphylococcus epidermidis ATCC 35984. A different behavior from pristine CuO NPs was observed, depending on the aminoacidic side chain. These results were supported by physico-chemical and colloidal characterization carried out by means of Fourier-Transform Infrared spectroscopy (FTIR), Differential Scanning Calorimetry (DSC) and Thermo-Gravimetric Analysis (TGA), Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and light scattering techniques (Dynamic Light Scattering (DLS), Electrophoretic Light Scattering (ELS) and Centrifugal Separation Analysis (CSA).

The SOUL protein is known to induce apoptosis by provoking the mitochondrial permeability transition, and a sequence homologous with the BH3 (Bcl-2 homology 3) domains has recently been identified in the protein, thus making it a potential new member of the BH3-only protein family. In the present study, we provide NMR, SPR (surface plasmon resonance) and crystallographic evidence that a peptide spanning residues 147–172 in SOUL interacts with the anti-apoptotic protein Bcl-xL. We have crystallized SOUL alone and the complex of its BH3 domain peptide with Bcl-xL, and solved their three-dimensional structures. The SOUL monomer is a single domain organized as a distorted β-barrel with eight anti-parallel strands and two α-helices. The BH3 domain extends across 15 residues at the end of the second helix and eight amino acids in the chain following it. There are important structural differences in the BH3 domain in the intact SOUL molecule and the same sequence bound to Bcl-xL.

Implantable devices need specific tailored surface morphologies and chemistries to interact with the living systems or to actively induce a biological response also by the release of drugs or proteins. These customised requirements foster technologies that can be implemented in additive manufacturing systems. Here we present a novel approach based on spraying processes that allows to control separately topographic features in the submicron range (∽ 60 nm - 2 µm), ammine or carboxylic chemistry and fluorophore release even on temperature sensitive biodegradable polymers such as polycaprolactone (PCL). We developed a two-steps process with a first deposition of 220 nm silica and poly(lactic-co-glycolide) (PLGA) fluorescent nanoparticles by aerosol followed by the deposition of a fixing layer by atmospheric pressure plasma jet (APPJ). The nanoparticles can be used to create the nano-roughness and to include active molecule release, while the capping layer ensures stability and the chemical functionalities. The process is enabled by a novel APPJ which allows deposition rates of 10 - 20 nm·s^-1 at temperatures lower than 50 °C using argon as process gas. This approach was assessed on titanium alloys for dental implants and on PCL films. The surfaces were characterized by FT-IR, AFM and SEM. Titanium alloys were tested with pre-osteoblasts murine cells line, while PCL film with fibroblasts. Cell behaviour was evaluated by viability and adhesion assays, protein adsorption, cell proliferation, focal adhesion formation and SEM. The release of a fluorophore molecule was assessed in the cell growing media, simulating a drug release. Osteoblast adhesion on the plasma treated materials increased by 20% with respect to commercial titanium alloys implants. Fibroblast adhesion increased by a 100% compared to smooth PCL substrate. The release of the fluorophore by the dissolution of the PLGA nanoparticles was verified and the integrity of the encapsulated drug model confirmed.